Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $93.5 million.

  • Precision Biosciences' Liabilities and Shareholders Equity fell 3898.52% to $93.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $463.2 million, marking a year-over-year decrease of 3019.12%. This contributed to the annual value of $136.4 million for FY2024, which is 1464.07% down from last year.
  • As of Q3 2025, Precision Biosciences' Liabilities and Shareholders Equity stood at $93.5 million, which was down 3898.52% from $108.9 million recorded in Q2 2025.
  • In the past 5 years, Precision Biosciences' Liabilities and Shareholders Equity registered a high of $297.2 million during Q2 2022, and its lowest value of $93.5 million during Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $181.7 million (2023), whereas its average is $189.3 million.
  • Per our database at Business Quant, Precision Biosciences' Liabilities and Shareholders Equity surged by 4085.03% in 2021 and then crashed by 3952.0% in 2023.
  • Precision Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $211.5 million in 2021, then grew by 12.61% to $238.2 million in 2022, then tumbled by 32.91% to $159.8 million in 2023, then decreased by 14.64% to $136.4 million in 2024, then plummeted by 31.44% to $93.5 million in 2025.
  • Its last three reported values are $93.5 million in Q3 2025, $108.9 million for Q2 2025, and $124.4 million during Q1 2025.